Ipamorelin + Tesamorelin (10mg)
Blend of Tesamorelin (5 mg, a 44-amino acid synthetic GHRH analog, FDA-approved as Egrifta® for visceral fat reduction) and Ipamorelin (5 mg, a selective ghrelin pentapeptide). Together they produce synergistic GH pulses via dual GHRH + ghrelin action. Administered once daily subcutaneously with gradual titration.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
Tesamorelin (FDA-approved as Egrifta®) is a 44-amino acid synthetic GHRH analog, identical to endogenous GHRH except for a trans-3-hexenoic acid modification at the N-terminus. It binds to the GHRH-R on somatotroph cells of the anterior pituitary, stimulating prolonged GH secretion. Ipamorelin binds to the GHS-R1a (ghrelin receptor), selectively stimulating GH without increasing ACTH, cortisol, or prolactin. The combination of a GHRH + ghrelin-mimetic produces **synergistic GH pulses** significantly greater than either peptide alone.
Quick Start
- Reconstitution: Add 3.0 mL of bacteriostatic water → ~3.33 mg/mL (1.67 mg/mL per peptide).
- Typical Daily Range: 250–1,500 mcg/peptide (0.5–3.0 mg total) with a 16-week gradual titration.
- Storage: Lyophilized: 2–8 °C · after reconstitution: 2–8 °C · use within 24–48 hours (Tesamorelin degrades rapidly).
Gradual Titration (3 mL = ~3.33 mg/mL)
Route: Subcutaneously | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 250 mcg/peptide (0.5 mg total) | 15 Units (0.15 mL) |
| Weeks 3–4 | 500 mcg/peptide (1.0 mg total) | 30 Units (0.30 mL) |
| Weeks 5–8 | 750 mcg/peptide (1.5 mg total) | 45 Units (0.45 mL) |
| Weeks 9–12 | 1,000 mcg/peptide (2.0 mg total) | 60 Units (0.60 mL) |
| Weeks 13–16 | 1,500 mcg/peptide (3.0 mg total) | 90 Units (0.90 mL) |
Studies report administration once daily subcutaneously. Large volumes (≥1 mL) can be split into 2 injection sites. Tesamorelin degrades rapidly after reconstitution — reconstitute only before use. Timing: morning or evening.
Reconstitution Steps
- Draw 3.0 mL of bacteriostatic water with a sterile syringe.
- Slowly inject down the side wall of the vial · avoid foaming.
- Swirl gently until fully dissolved (do not shake vigorously).
- IMPORTANT: Use within 24–48 hours — Tesamorelin degrades rapidly after reconstitution.
- Refrigerate at 2–8 °C immediately · do not freeze reconstituted solution.
Protocol Overview
- Goal: Synergistic increase in GH/IGF-1 via dual GHRH (tesamorelin) + ghrelin (ipamorelin) action.
- Schedule: Daily subcutaneous injections for 8–16 weeks, with gradual titration.
- Storage: Lyophilized refrigerated · reconstituted refrigerated · do not freeze when reconstituted.
Dosing Protocol
- Start: 250 mcg/peptide daily (15 units) to assess tolerance.
- Increase: Every 2–4 weeks: 500 → 750 → 1,000 → 1,500 mcg/peptide.
- Target: 1,000–1,500 mcg/peptide (wk 9–16).
- Timing: Morning or evening · at a consistent time.
- Cycle Duration: 8–16 weeks · Tesamorelin is used long-term in its FDA-approved indication.
- Break between cycles: After the cycle, a 4–8 week pause is recommended. The Ipamorelin + Tesamorelin combination potently stimulates GH — a pause helps restore natural regulation.
Washout & Cycle Restart
When can I restart?
After the cycle, a 4–8 week pause is recommended. The Ipamorelin + Tesamorelin combination potently stimulates GH — a pause helps restore natural regulation.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: 2–8 °C (Tesamorelin should not be frozen in certain formulations).
- Reconstituted: 2–8 °C · use within 24–48 hours — Tesamorelin degrades rapidly.
- Reconstitute vial immediately before use if possible · do not freeze once reconstituted.
Important Notes
- CRITICAL: Tesamorelin degrades quickly — use within 24–48 hours after reconstitution.
- Monitor IGF-1 and glucose during long cycles.
Potential Benefits & Side Effects
Potential Benefits:
- Synergistic increase in GH/IGF-1 via two complementary pathways.
- Reduction of visceral fat (FDA-approved indication for tesamorelin).
- Improved body composition — muscle mass ↑, body fat ↓.
- Selective action of Ipamorelin — no increase in cortisol, ACTH, or prolactin.
- Improved sleep quality and recovery.
Potential Side Effects:
- Mild injection site reaction (redness, pain).
- Transient arthralgia or edema (especially at high doses).
- Altered insulin sensitivity — monitor glucose.
- Rare: transient numbness/tingling.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Theoretical neoplasia risk (IGF-1 elevation)
Tesamorelin increases GH/IGF-1. Contraindicated in active neoplasia. No significant signal observed in clinical trials.
📄 FDA Label — Egrifta®Theoretical risk (GH/IGF-1 elevation)
As a GHS, increases GH. Theoretical risk for pre-existing neoplasms due to IGF-1 elevation. No clinical signal in short-term studies.
📄 Growth Horm IGF Res 2008References
- N Engl J Med — Tesamorelin reduces visceral fat in HIV-lipodystrophy
View Source - Growth Hormone & IGF Research — Ipamorelin: selective GH action without ACTH/cortisol
View Source - Eur J Endocrinol — Ipamorelin: the first selective GH secretagogue
View Source - Endocrine Reviews — GH secretagogues: mechanisms & clinical applications
View Source - J Acquir Immune Defic Syndr — Tesamorelin: long-term safety & efficacy
View Source
External Sources & Regulatory Status
Regulatory Approvals
Egrifta® · HIV lipodystrophy (2010)
Egrifta® · HIV lipodystrophy (2015)
FDA + Health Canada approved
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →